Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:10286
Name prostate carcinoma
Definition A prostate cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer male reproductive organ cancer prostate cancer prostate carcinoma


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
RB1 mut TP53 mut R547 prostate carcinoma sensitive detail...
PTEN loss SAR260301 prostate carcinoma decreased response detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01385228 Phase I Docetaxel + Pazopanib + Pegfilgrastim Pazopanib, Docetaxel, Prednisone Prostate Completed USA 0
NCT01391143 Phase I MGA271 Safety Study of MGA271 in Refractory Cancer Completed USA 0
NCT01561482 Phase II Metformin + Simvastatin Study of Metformin With Simvastatin for Men With Prostate Carcinoma Withdrawn USA 0
NCT02113657 Phase II Ipilimumab T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer Completed USA 0
NCT02234115 Phase III Leuprolide Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma Completed USA | DEU | AUT 5
NCT02516553 Phase I BI 894999 BI 894999 First in Human Dose Finding Study in Advanced Malignancies Completed USA | FRA | ESP | DEU | BEL 1
NCT02552394 Phase I J591 J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts Completed USA 0
NCT02565901 Phase Ib/II Carboplatin + Docetaxel + Sirolimus Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Terminated USA 0
NCT02723955 Phase I GSK3359609 GSK3359609 + Pembrolizumab Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) Completed USA | NLD | ITA | FRA | ESP | CAN | AUS 2
NCT02952534 Phase II Rucaparib A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 3
NCT02975934 Phase III Rucaparib Docetaxel Enzalutamide Abiraterone A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 3
NCT03261999 Phase III Leuprolide Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer Completed USA 4
NCT03263650 Phase II Cabazitaxel + Carboplatin Olaparib Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC Active, not recruiting USA 0
NCT03336983 Phase II Enzalutamide + Triptorelin Enzalutamide + Triptorelin + Zoledronic acid Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients Unknown status ITA 0
NCT03837353 Phase Ib/II DKN-01 DKN-01 + Docetaxel A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1 Terminated USA 0
NCT04179396 Phase I Enzalutamide + Rucaparib Abiraterone + Rucaparib Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) (RAMP) Completed USA 0
NCT04388852 Phase I DS-3201b + Ipilimumab DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers Recruiting USA 0
NCT04514484 Phase I Cabozantinib + Nivolumab Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Active, not recruiting USA 0
NCT04592237 Phase II Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer Active, not recruiting USA 0
NCT04631744 Phase II Cabozantinib Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Recruiting USA 0
NCT04709276 Phase II Cabazitaxel + Carboplatin + Ipilimumab + Nivolumab A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP) Recruiting USA 0
NCT04947254 Phase II Apalutamide Abiraterone + Apalutamide + Niraparib + Prednisone Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer Recruiting USA 0
NCT05169684 Phase II BMS-986218 + Docetaxel Docetaxel BMS-986218 + Nivolumab BMS-986218 + Docetaxel + Nivolumab A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer Completed USA | NLD | ITA | GBR | FRA | CAN 2
NCT05265988 Phase II Cabozantinib Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib (MERIDIAN) Unknown status ITA 0